The group 's principal activities are to design, develop and manufacture proprietary line of absorbable medical devices. the devices are used for the sealing of arterial punctures created during diagnostic and therapeutic cardiovascular procedures such as angiography, angioplasty and the placement of stents. the group's principal product, the 8f size angio-seal device has been designed to provide safe, effective and rapid method of sealing arterial punctures. in addition, the group manufactures collagen used for musculoskeletal repair. the group has a strategic relationship with ahp whereby ahp will manufacture and market the angio-seal product line worldwide. proprietary medical devices accounted for 60% of fiscal 2002 revenues; Royalty income, 37% and research and development, 3%.